The tumor-promoting role of TROAP has been experimentally validated in several preclinical cancer models, including breast, kidney, liver, and prostate cancer (Li K. et al., 2019; Jin et al., 2020; Li L. et al., 2021; Wang et al., 2023; Yue et al., 2023). Here, TROAP is linked to cancer.